Improving triage and management of patients with skin cancer: Challenges and considerations for the future

Expert Review of Anticancer Therapy

Volumn 12, Issue 5, 2012, Pages 609-621

  Argenziano, Giuseppe ^a   Giacomel, Jason ^b   Abramavicus, Alexandre ^c   Pellacani, Giovanni ^d   Longo, Caterina ^a   De Pace, Barbara ^a   Albertini, Giuseppe ^a   Cristofolini, Mario ^e   Zalaudek, Iris ^f  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b Mends St Medical Centre   (Australia)

^c School of Speech Language Pathology and Audiology   (Brazil)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e Italian League Against Cancer   (Italy)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

clinical diagnosis; dermatoscopy; dermoscopy; management; melanoma; skin cancer

Indexed keywords

ALGORITHM; BASAL CELL CARCINOMA; CANCER PATIENT; CANCER PREVENTION; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PROTOCOL; COMPUTER ASSISTED TOMOGRAPHY; CONFOCAL LASER MICROSCOPY; CONGENITAL NEVUS; DERMATOLOGIST; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISTANT METASTASIS; DYSPLASTIC NEVUS; EARLY DIAGNOSIS; EPILUMINESCENCE MICROSCOPY; FOLLOW UP; GENERAL PRACTITIONER; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IN-TRANSIT METASTASIS; MALIGNANT TRANSFORMATION; MEDICAL EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PAPULE; PATIENT CARE; PATIENT MONITORING; PATIENT SELECTION; PRACTICE GUIDELINE; PRIMARY MEDICAL CARE; PRIMARY TUMOR; REOPERATION; REVIEW; SATELLITE METASTASIS; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; SKIN BIOPSY; SKIN CANCER; SKIN CARE; SKIN DEFECT; SKIN EXAMINATION; SKIN MANIFESTATION; SKIN NODULE; SKIN PIGMENTATION; SKIN SURGERY; STANDARDIZATION; SURVIVAL RATE; SURVIVAL TIME;

AGE FACTORS; DERMATOLOGY; EARLY DETECTION OF CANCER; GENERAL PRACTICE; HUMANS; MELANOMA; REFERRAL AND CONSULTATION; SKIN NEOPLASMS; TRIAGE;

EID: 84861311914     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.38     Document Type: Review

References (73)

1. Coory M, Baade P, Aitken J, Smithers M, McLeod GRC, Ring I. Trends for in situ and invasive melanoma in Queensland, Australia, 1982-2002. Cancer Causes Control 17(1), 21-27 (2006).
2. Buettner PG, Raasch BA. Incidence rates of skin cancer in Townsville, Australia. Int. J. Cancer 78(5), 587-593 (1998).
3. Cox NH. Evaluation of the U.K. 2-week referral rule for skin cancer. Br. J. Dermatol. 150(2), 291-298 (2004).
4. Argenziano G, Puig S, Zalaudek I et al. Dermoscopy improves accuracy of primary care physicians to triage lesions suggestive of skin cancer. J. Clin. Oncol. 24(12), 1877-1882 (2006).
5. Giacomel J. Are superficial basal cell carcinomas the most common cancer in the Australian community? Cancer Forum 28(1), 34 (2004).
6. Soyer HP, Argenziano G, Zalaudek I et al. Three-point checklist of dermoscopy. A new screening method for early detection of melanoma. Dermatology 208(1), 27-31 (2004).
7. Price HN, Schaffer JV. Congenital melanocytic nevi-when to worry and how to treat: facts and controversies. Clin. Dermatol. 28(3), 293-302 (2010).
8. Schaffer JV. Pigmented lesions in children: when to worry. Curr. Opin. Pediatr. 19(4), 430-440 (2007).
9. Moscarella E, Zalaudek I, Ferrara G, Manzo M, Savarese I, Argenziano G. Problematic melanocytic lesions in children. Expert Rev. Dermatol. 4(3), 249-261 (2009).
10. Paradela S, Fonseca E, Pita S et al. Spitzoid melanoma in children: clinicopathological study and application of immunohistochemistry as an adjunct diagnostic tool. J. Cutan. Pathol. 36(7), 740-752 (2008).
11. Tom WL, Hsu JW, Eichenfield LF, Friedlander SF. Pediatric 'STUMP' lesions: evaluation and management of difficult atypical Spitzoid lesions in children. J. Am. Acad. Dermatol. 64(3), 559-572 (2011).
12. Lewis KG. Trends in pediatric melanoma mortality in the United States, 1968 through 2004. Dermatol. Surg. 34(2), 152-159 (2008).
13. Bauer J, Garbe C. Acquired melanocytic nevi as risk factor for melanoma development. A comprehensive review of epidemiological data. Pigment Cell Res. 16(3), 297-306 (2003).
14. Quéreux G, Moyse D, Lequeux Y et al. Development of an individual score for melanoma risk. Eur. J. Cancer Prev. 20(3), 217-224 (2011).
15. Abbasi NR, Shaw HM, Rigel DS et al. Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA 292(22), 2771-2776 (2004).
16. Thomas L, Tranchand P, Berard F, Secchi T, Colin C, Moulin G. Semiological value of ABCDE criteria in the diagnosis of cutaneous pigmented tumors. Dermatology 197(1), 11-17 (1998).
17. Kelly JW, Chamberlain AJ, Staples MP, McAvoy B. Nodular melanoma. No longer as simple as ABC. Aust. Fam. Physician 32(9), 706-709 (2003).
18. Chamberlain AJ, Fritschi L, Kelly JW. Nodular melanoma: patients' perceptions of presenting features and implications for earlier detection. J. Am. Dermatol. 48(5), 694-701 (2003).
19. Argenziano G, Zalaudek I, Hofmann- Wellenhof R et al. Total body skin examination for skin cancer screening in patients with focused symptoms. J. Am. Acad. Dermatol. 66(2), 212-219 (2012).
20. Argenziano G, Soyer HP, Chimenti S et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J. Am. Acad. Dermatol. 48(5), 679-693 (2003).
21. Bafounta ML, Beauchet A, Aegerter P, Saiag P. Is dermoscopy (epiluminescence microscopy) useful for the diagnosis of melanoma? Results of a meta-analysis using techniques adapted to the evaluation of diagnostic tests. Arch. Dermatol. 137(10), 1343-1350 (2001).
22. Kittler H, Pehamberger H, Wolff K, Binder M. Diagnostic accuracy of dermoscopy. Lancet Oncol. 3(3), 159-165 (2002).
23. Carli P, De Giorgi V, Chiarugi A et al. Addition of dermoscopy to conventional naked-eye examination in melanoma screening: a randomized study. J. Am. Acad. Dermatol. 50(5), 683-689 (2004).
24. Carli P, De Giorgi V, Crocetti E et al. Improvement of malignant/benign ratio in excised melanocytic lesions in the 'dermoscopy era': a retrospective study 1997-2001. Br. J. Dermatol. 150(4), 687-692 (2004).
25. Vestergaard ME, Macaskill P, Holt PE, Menzies SW. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br. J. Dermatol. 159(3), 669-676 (2008).
26. Argenziano G, Cerroni L, Zalaudek I et al. Accuracy in melanoma detection: a 10-year multicenter survey. J. Am. Acad. Dermatol. doi:10.1016/j.jaad.2011.07.019 (2011) (Epub ahead of print).
27. Zalaudek I, Kittler H, Marghoob AA et al. Time required for a complete skin examination with and without dermoscopy: a prospective, randomized multicenter study. Arch. Dermatol. 144(4), 509-513 (2008).
28. Argenziano G, Ferrara G, Francione S, Di Nola K, Martino A, Zalaudek I. Dermoscopy - the ultimate tool for melanoma diagnosis. Semin. Cutan. Med. Surg. 28(3), 142-148 (2009).
29. Kittler H, Seltenheim M, Dawid M, Pehamberger H, Wolff K, Binder M. Morphologic changes of pigmented skin lesions: a useful extension of the ABCD rule for dermatoscopy. J. Am. Acad. Dermatol. 40(4), 558-562 (1999).
30. Menzies SW, Emery J, Staples M et al. Impact of dermoscopy and short-term sequential digital dermoscopy imaging for the management of pigmented lesions in primary care: a sequential intervention trial. Br. J. Dermatol. 161(6), 1270-1277 (2009).
31. Malvehy J, Puig S. Follow-up of melanocytic skin lesions with digital total-body photography and digital dermoscopy: a two-step method. Clin. Dermatol. 20(3), 297-304 (2002).
32. Geller AC, O'Riordan DL, Oliveria SA, Valvo S, Teich M, Halpern AC. Overcoming obstacles to skin cancer examinations and prevention counseling for high-risk patients: results of a national survey of primary care physicians. J. Am. Board Fam. Pract. 17(6), 416-423 (2004).
33. Geller AC, Koh HK, Miller DR, Clapp RW, Mercer MB, Lew RA. Use of health services before the diagnosis of melanoma: implications for early detection and screening. J. Gen. Intern. Med. 7(2), 154-157 (1992).
34. Menzies SW, Gutenev A, Avramidis M, Batrac A, McCarthy WH. Short-term digital surface microscopic monitoring of atypical or changing melanocytic lesions. Arch. Dermatol. 137(12), 1583-1589 (2001).
35. Argenziano G, Zalaudek I, Ferrara G et al. Dermoscopy features of melanoma incognito: indications for biopsy. J. Am. Acad. Dermatol. 56(3), 508-513 (2007).
36. Zalaudek I, Argenziano G, Ferrara G et al. Clinically equivocal melanocytic skin lesions with features of regression: a dermoscopic-pathological study. Br. J. Dermatol. 150(1), 64-71 (2004).
37. Argenziano G, Kittler H, Ferrara G et al. Slow-growing melanoma: a dermoscopy follow-up study. Br. J. Dermatol. 162(2), 267-273 (2010).
38. Altamura D, Avramidis M, Menzies SW. Assessment of the optimal interval for and sensitivity of short-term sequential digital dermoscopy monitoring for the diagnosis of melanoma. Arch. Dermatol. 144(4), 502-506 (2008).
39. Pellacani G, Guitera P, Longo C, Avramidis M, Seidenari S, Menzies S. The impact of in vivo reflectance confocal microscopy for the diagnostic accuracy of melanoma and equivocal melanocytic lesions. J. Invest. Dermatol. 127(12), 2759-2765 (2007).
40. Guitera P, Pellacani G, Crotty KA et al. The impact of in vivo reflectance confocal microscopy on the diagnostic accuracy of lentigo maligna and equivocal pigmented and nonpigmented macules of the face. J. Invest. Dermatol. 130(8), 2080-2091 (2010).
41. Pellacani G, Cesinaro AM, Seidenari S. Reflectance-mode confocal microscopy of pigmented skin lesions-improvement in melanoma diagnostic specificity. J. Am. Acad. Dermatol. 53(6), 979-985 (2005).
42. Gerger A, Koller S, Kern T et al. Diagnostic applicability of in vivo confocal laser scanning microscopy in melanocytic skin tumors. J. Invest. Dermatol. 124(3), 493-498 (2005).
43. Busam KJ, Hester K, Charles C et al. Detection of clinically amelanotic malignant melanoma and assessment of its margins by in vivo confocal scanning laser microscopy. Arch. Dermatol. 137(7), 923-929 (2001).
44. Braga JCT, Scope A, Klaz I et al. The significance of reflectance confocal microscopy in the assessment of solitary pink skin lesions. J. Am. Acad. Dermatol. 61(2), 230-241 (2009).
45. Suh K-Y, Bolognia JL. Signature nevi. J. Am. Acad. Dermatol. 60(3), 508-514 (2009).
46. Scope A, Dusza SW, Halpern AC et al. The 'ugly duckling' sign: agreement between observers. Arch. Dermatol. 144(1), 58-64 (2008).
47. Argenziano G, Catricalà C, Ardigo M et al. Dermoscopy of patients with multiple nevi: Improved management recommendations using a comparative diagnostic approach. Arch. Dermatol. 147(1), 46-49 (2011).
48. Haenssle HA, Korpas B, Hansen-Hagge C et al. Selection of patients for long-term surveillance with digital dermoscopy by assessment of melanoma risk factors. Arch. Dermatol. 146(3), 257-264 (2010).
49. Haenssle HA, Krueger U, Vente C et al. Results from an observational trial: digital epiluminescence microscopy follow-up of atypical nevi increases the sensitivity and the chance of success of conventional dermoscopy in detecting melanoma. J. Invest. Dermatol. 126(5), 980-985 (2006).
50. Kittler H, Guitera P, Riedl E et al. Identification of clinically featureless incipient melanoma using sequential dermoscopy imaging. Arch. Dermatol. 142(9), 1113-1119 (2006).
51. Kittler H, Binder M. Risks and benefits of sequential imaging of melanocytic skin lesions in patients with multiple atypical nevi. Arch. Dermatol. 137(12), 1590-1595 (2001).
52. Marghoob AA, Kopf AW, Rigel DS et al. Risk of cutaneous malignant melanoma in patients with 'classic' atypical-mole syndrome. A case-control study. Arch. Dermatol. 130(8), 993-998 (1994).
53. Argenziano G, Mordente I, Ferrara G, Sgambato A, Annese P, Zalaudek I. Dermoscopic monitoring of melanocytic skin lesions: clinical outcome and patient compliance vary according to follow-up protocols. Br. J. Dermatol. 159(2), 331-336 (2008).
54. Banky JP, Kelly JW, English DR, Yeatman JM, Dowling JP. Incidence of new and changed nevi and melanomas detected using baseline images and dermoscopy in patients at high risk for melanoma. Arch. Dermatol. 141(8), 998-1006 (2005).
55. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol. 27(36), 6199-6206 (2009).
56. Balch CM, Buzaid AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19(16), 3635-3648 (2001).
57. Morton DL, Thompson JF, Cochran AJ et al. Sentinel-node biopsy or nodal observation in melanoma. N. Engl. J. Med. 355(13), 1307-1317 (2006).
58. Medalie NS, Ackerman AB. Sentinel lymph node biopsy has no benefit for patients with primary cutaneous melanoma metastatic to a lymph node: an assertion based on comprehensive, critical analysis: part I. Am. J. Dermatopathol. 25(5), 399-417 (2003).
59. Medalie NS, Ackerman AB. Sentinel lymph node biopsy has no benefit for patients with primary cutaneous melanoma metastatic to a lymph node: an assertion based on comprehensive, critical analysis: part II. Am. J. Dermatopathol. 25(6), 473-484 (2003).
60. Gonzàlez U. Cloud over sentinel node biopsy: unlikely survival benefit in melanoma. Arch. Dermatol. 143(6), 775-776 (2007).
61. Broer N, Buonocore S, Goldberg C et al. A proposal for the timing of management of patients with melanoma presenting during pregnancy. J. Surg. Oncol. doi:10.1002/jso.23035 (2012) (Epub ahead of print).
62. Ackerman AB. A centimeter here, a centimeter there. J. Am. Acad. Dermatol. 35(2 Pt 1), 279-280 (1996).
63. Ackerman AB, Scheiner AM. How wide and deep is wide and deep enough? A critique of surgical practice in excisions of primary cutaneous malignant melanoma. Hum. Pathol. 14(9), 743-744 (1983).
64. Bono A, Bartoli C, Clemente C et al. Ambulatory narrow excision for thin melanoma. Eur. J. Cancer 33(8), 1330-1332 (1997).
65. Gillgren P, Drzewiecki KT, Niin M et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet 378(9803), 1635-1642 (2011).
66. Garbe C, Paul A, Kohler-Späth H et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J. Clin. Oncol. 21(3), 520-529 (2003).
67. McLoughlin JM, Zager JS, Sondak VK, Berk LB. Treatment options for limited or symptomatic metastatic melanoma. Cancer Control 15(3), 239-247 (2008).
68. Heaston DK, Putman CE, Rodan BA et al. Solitary pulmonary metastases in high-risk melanoma patients: a prospective comparison of conventional and computed tomography. AJR Am. J. Roentgenol. 141(1), 169-174 (1983).
69. Prayer L, Winkelbauer H, Gritzmann N, Winkelbauer F, Helmer M, Pehamberger H. Sonography versus palpation in the detection of regional lymph-node metastases in patients with malignant melanoma. Eur. J. Cancer 26(7), 827-830 (1990).
70. Strobel K, Skalsky J, Steinert HC et al. S-100B and FDG-PET/CT in therapy response assessment of melanoma patients. Dermatology 215(3), 192-201 (2007).
71. Brady MS, Akhurst T, Spanknebel K et al. Utility of preoperative [(18)]F fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. Ann. Surg. Oncol. 13(4), 525-532 (2006).
72. Savoia P, Osella-Abate S, Deboli T et al. Clinical and prognostic reports from 270 patients with multiple primary melanomas: a 34-year single-institution study. J. Eur. Acad. Dermatol. Venereol. (2011).
73. Moseley HS, Giuliano AE, Storm FK, Clark WH, Robinson DS, Morton DL. Multiple primary melanoma. Cancer 43(3), 939-944 (1979).